Tonix Pharmaceuticals Holding Corp (FRA:TPM0) Stock Price, Trades & News

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Financial Strength

7/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	143.78
Equity-to-Asset	0.88
Debt-to-Equity	0.01
Debt-to-EBITDA	-0.01
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-1.88	Distress Grey Safe
Beneish M-Score	-1.37	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	93.6
	3-Year EPS without NRI Growth Rate	93.9
	3-Year FCF Growth Rate	94.5
	3-Year Book Growth Rate	-92.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	37.98
	Future 3-5Y Total Revenue Growth Rate Estimate	131.59

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	40.7
	9-Day RSI	49.15
	14-Day RSI	50.06
	3-1 Month Momentum %	-9.55
	6-1 Month Momentum %	-23.16
	12-1 Month Momentum %	-96.51

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	6.99
	Quick Ratio	6.83
	Cash Ratio	6.26
	Days Inventory	316.17
	Days Sales Outstanding	100.64
	Days Payable	384.11

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1373.2
	Shareholder Yield %	-88.1

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	58.56
	Operating Margin %	-849.27
	Net Margin %	-839.52
	EBITDA Margin %	-830.09
	FCF Margin %	-743.81
	OCF Margin %	-714.84
	ROE %	-70.06
	ROA %	-63.11
	ROIC %	-267.65
	3-Year ROIIC %	26.62
	ROC (Joel Greenblatt) %	-328.61
	ROCE %	-70.01
	Moat Score	4
	Tariff Resilience Score	7

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	7.99
	PB Ratio	0.8
	Price-to-Tangible-Book	0.8
	EV-to-EBIT	-0.13
	EV-to-EBITDA	-0.13
	EV-to-Revenue	1.1
	EV-to-Forward-Revenue	0.64
	EV-to-FCF	-0.15
	Price-to-GF-Value	7.3
	Price-to-Net-Current-Asset-Value	1.03
	Price-to-Net-Cash	1.17
	Earnings Yield (Greenblatt) %	-769.23
	FCF Yield %	-64.18

Financials (Next Earnings Date:2026-08-11 Est.)

Annual Quarterly TTM

FRA:TPM0's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Tonix Pharmaceuticals Holding Corp Executives

Details

GF Value™: €1.44

FRA:TPM0

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with TPM0. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	15.087
	EPS (TTM) (€)	-12.339
	Beta	0.1829
	3-Year Sharpe Ratio	-0.8
	3-Year Sortino Ratio	-0.79
	Volatility %	95.31
	14-Day RSI	50.06
	14-Day ATR (€)	0.291269
	20-Day SMA (€)	10.3201
	12-1 Month Momentum %	-96.51
	52-Week Range (€)	8.852 - 282
	Shares Outstanding (Mil)	15.94

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Tonix Pharmaceuticals Holding Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Tonix Pharmaceuticals Holding Corp Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-11-10	In 123 days
Second quarter earnings results for 2026	2026-08-11	In 32 days
A.G.P.\'s Annual Virtual Healthcare Conference	2026-05-20 15:00	11.91 (+0.00%)
RBC Capital Markets Global Healthcare Conference	2026-05-19 13:35	11.96 (-7.86%)
First quarter earnings results for 2026	2026-05-11	11.69 (-2.67%)
General meeting for 2026	2026-05-07 11:00	12.04 (+8.03%)
Annual report for 2025	2026-03-12	11.90 (+0.85%)
Fourth quarter earnings results for 2025	2026-03-12	11.90 (+0.85%)
Barclays 28(th) Annual Healthcare Conference	2026-03-10	12.40 (+10.71%)
TD Cowen 46(th) Annual Healthcare Conference	2026-03-04 11:10	11.80 (+2.61%)

Show

Entries

Tonix Pharmaceuticals Holding Corp Frequently Asked Questions

What is Tonix Pharmaceuticals Holding Corp(FRA:TPM0)'s stock price today?

The current price of FRA:TPM0 is €10.52. The 52 week high of FRA:TPM0 is €282.00 and 52 week low is €8.85.

When is next earnings date of Tonix Pharmaceuticals Holding Corp(FRA:TPM0)?

The next earnings date of Tonix Pharmaceuticals Holding Corp(FRA:TPM0) is 2026-08-11 Est..

Does Tonix Pharmaceuticals Holding Corp(FRA:TPM0) pay dividends? If so, how much?

Tonix Pharmaceuticals Holding Corp(FRA:TPM0) does not pay dividend.

Press Release

	Subject	Date
	Tonix's Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year	2025-03-31
	As Mpox Cases Spread Around the World, Tonix Pharmaceuticals' Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread	2025-03-20
	Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target	2025-03-12
	Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers	2024-12-09
	Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments	2024-11-14
	The Rush for Non-Addictive Painkillers to Counter the Opioid Crisis Puts Two Companies Close to FDA Decisions	2024-10-01
	New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution	2024-09-18
	As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront -- Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL	2024-09-04
	Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency	2024-08-23
	Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency	2024-08-23

10/Page

Articles on Tonix Pharmaceuticals Holding Corp

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.